Prognostic significance of adipocytokines and extracellular matrix activity in heart failure patients with high B-type natriuretic peptide

Clinical Biochemistry

Volumn 42, Issue 13-14, 2009, Pages 1407-1412

  Ho, Yi Lwun ^a   Lin, Yen Hung ^a   Lee, Chi Ming ^a   Hsu, Ron Bin ^a   Ting, Hsiu Tzu ^a   Chou, Nai Kuan ^a   Chao, Chia Lun ^a   Wang, Shoei Shen ^a   Hsu, Hsiu Ching ^a   Chen, Ming Fong ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Adiponectin; b type natriuretic peptide; Extracellular matrix; Heart failure

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APELIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; LOOP DIURETIC AGENT; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RESISTIN; SPIRONOLACTONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ADIPOKINES; ADIPONECTIN; AGED; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIERS ESTIMATE; LINEAR MODELS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RESISTIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 69249229547     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.06.013     Document Type: Article

References (35)

1. Han S.H., Quon M.J., Kim J.A., and Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic intervention. J. Am. Coll. Cardiol. 49 (2007) 531-538
2. Kistorp C., Faber J., Galatius S., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112 (2005) 1756-1762
3. George J., Patal S., Wexler D., et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92 (2006) 1420-1424
4. Tamura T., Furukawa Y., Taniguchi R., et al. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ. J. 71 (2007) 623-630
5. Tsutamoto T., Tanaka T., Sakai H., et al. Total and high molecular weight adiponectin, hemodynamics, and mortality in patients with chronic heart failure. Eur. Heart J. 28 (2007) 1723-1730
6. McEntegart M.B., Awede B., Petrie M.C., et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J. 28 (2007) 829-835
7. Beltowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?. Med. Sci. Monit. 12 (2006) RA112-9
8. Takeishi Y., Niizeki T., Arimoto T., et al. Serum resistin is associated with high risk in patients with congestive heart failure-a novel link between metabolic signals and heart failure. Circ. J. 71 (2007) 460-464
9. Schulze P.C., and Kratzsch J. Leptin as a new diagnostic tool in chronic heart failure. Clin. Chim. Acta. 362 (2005) 1-11
10. Cicoira M., Rossi A., Bonapace S., et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J. Card. Fail. 10 (2004) 403-411
11. Reinhardt D., Sigusch H.H., Hensse J., Tyagi S.C., Korfer R., and Figulla H.R. Cardiac remodeling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 88 (2002) 525-530
12. George J., Patal S., Wexler D., Roth A., Sheps D., and Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am. Heart J. 150 (2005) 484-487
13. Yamazaki T., Lee J.D., Shimizu H., Uzui H., and Ueda T. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur. J. Heart Fail. 6 (2004) 41-45
14. Wilson E.M., Gunasinghe H.R., Coker M.L., et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J. Card. Fail. 8 (2002) 390-398
15. Hattori Y., Hattori S., Akimoto K., et al. Globular adiponectin activates nuclear factor-kappaB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes 56 (2007) 804-808
16. ACC/AHA. Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 104 (2001) 2996-3007
17. Ho Y.L., Hsu T.P., Chen C.P., et al. Improved cost-effectiveness for management of chronic heart failure by combined home-based intervention with clinical nursing specialists. J. Formos. Med. Assoc. 106 (2007) 313-319
18. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 (1997) 509-516
19. Latini R., Masson S., Anand I., et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur. Heart J. 25 (2004) 292-299
20. Anker S.D., Ponikowski P., Varney S., et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349 (1997) 1050-1053
21. Iwanaga Y., Aoyama T., Kihara Y., Onozawa Y., Yoneda T., and Sasayama S. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J. Am. Coll. Cardiol. 39 (2002) 1384-1391
22. Bergman M.R., Teerlink J.R., Mahimkar R., et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H1847-H1860
23. Wang G.Y., Bergman M.R., Nguyen A.P., et al. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc. Res. 69 (2006) 688-696
24. Lainscak M., von Haehling S., Springer J., and Anker S.D. Biomarkers for chronic heart failure. Heart Fail. Monit. 5 (2007) 77-82
25. Pascual-Figal D.A., Hurtado-Martínez J.A., Redondo B., Antolinos M.J., Ruiperez J.A., and Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur. J. Heart Fail. 9 (2007) 518-524
26. Leyva F., Anker S.D., Godsland I.F., et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur. Heart J. 19 (1998) 1814-1822
27. Horwich T.B., Hamilton M.A., Maclellan W.R., and Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J. Card. Fail. 8 (2002) 216-224
28. Afsarmanesh N., Horwich T.B., and Fonarow G.C. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am. Heart J. 152 (2006) 1077-1083
29. Anavekar N.S., McMurray J.J., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med. 351 (2004) 1285-1295
30. Hillege H.L., Nitsch D., Pfeffer M.A., et al. Candesartan in heart failure: assessment of Reduction in Mortality and Morbidity (CHARM) investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113 (2006) 671-678
31. Fruebis J., Tsao T.S., Javorschi S., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2005-2010
32. Waki H., Yamauchi T., Kamon J., et al. Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology 146 (2005) 790-796
33. Ding G., Qin Q., He N., et al. Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma. J. Mol. Cell. Cardiol. 43 (2007) 73-84
34. Horio T., Suzuki M., Suzuki K., et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am. J. Hypertens. 18 (2005) 949-957
35. Demirbag R., Yildiz A., Gur M., Yilmaz R., Elçi K., and Aksoy N. Serum prolidase activity in patients with hypertension and its relation with left ventricular hypertrophy. Clin. Biochem. 40 (2007) 1020-1025